Emerging Targeted Therapies for HER2-Positive Breast Cancer

SIMPLE SUMMARY: HER2-positive breast cancer (BC), which accounts for ~20% of BC, is one of the more aggressive and has the worst overall survival rate among them. These patients are treated with trastuzumab, a monoclonal antibody targeting the HER2 molecule. Even though trastuzumab is an effective t...

Descripción completa

Detalles Bibliográficos
Autores principales: Mercogliano, María Florencia, Bruni, Sofía, Mauro, Florencia Luciana, Schillaci, Roxana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093019/
https://www.ncbi.nlm.nih.gov/pubmed/37046648
http://dx.doi.org/10.3390/cancers15071987

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093019/
https://www.ncbi.nlm.nih.gov/pubmed/37046648
http://dx.doi.org/10.3390/cancers15071987

Ejemplares similares